MERSANA THERAPEUTICS INC's ticker is MRSN and the CUSIP is 59045L106. A total of 2 filers reported holding MERSANA THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,176 | -65.9% | 925,919 | -11.6% | 0.00% | -60.0% |
Q2 2023 | $3,448 | -32.9% | 1,047,919 | -16.2% | 0.01% | -28.6% |
Q1 2023 | $5,140 | +53.4% | 1,250,519 | +118.7% | 0.01% | +40.0% |
Q4 2022 | $3,350 | -99.9% | 571,719 | -18.2% | 0.01% | -28.6% |
Q3 2022 | $4,724,000 | +79.3% | 698,819 | +22.5% | 0.01% | +133.3% |
Q2 2022 | $2,635,000 | -28.2% | 570,319 | -38.0% | 0.00% | -25.0% |
Q1 2022 | $3,668,000 | +72.1% | 919,200 | +168.3% | 0.00% | +33.3% |
Q4 2021 | $2,131,000 | +60.1% | 342,600 | +379.2% | 0.00% | +200.0% |
Q3 2020 | $1,331,000 | -83.3% | 71,500 | -79.0% | 0.00% | -85.7% |
Q2 2020 | $7,962,000 | +74.3% | 340,268 | -56.6% | 0.01% | +75.0% |
Q1 2020 | $4,568,000 | +10.8% | 783,568 | +8.9% | 0.00% | +33.3% |
Q4 2019 | $4,124,000 | +240.5% | 719,768 | -6.1% | 0.00% | +200.0% |
Q3 2019 | $1,211,000 | +12.4% | 766,725 | +188.2% | 0.00% | 0.0% |
Q2 2019 | $1,077,000 | +17.3% | 266,020 | +52.4% | 0.00% | 0.0% |
Q1 2019 | $918,000 | – | 174,520 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Bain Capital Life Sciences Investors, LLC | 8,663,673 | $40,026,000 | 4.69% |
Opaleye Management Inc. | 1,047,000 | $4,837,000 | 2.18% |
Sarissa Capital Management LP | 4,299,297 | $19,863,000 | 2.00% |
Decheng Capital Management III (Cayman), LLC | 904,268 | $4,178,000 | 1.58% |
SILVERARC CAPITAL MANAGEMENT, LLC | 850,000 | $3,927,000 | 1.21% |
Orbimed Advisors | 9,011,437 | $41,633,000 | 0.75% |
Avoro Capital Advisors LLC | 7,550,000 | $34,881,000 | 0.69% |
Rock Springs Capital Management LP | 4,075,958 | $18,831,000 | 0.55% |
Artal Group S.A. | 2,200,000 | $10,164,000 | 0.54% |
DAFNA Capital Management LLC | 406,763 | $1,879,000 | 0.51% |